| Methods |
Allocation: randomised.
Blindness: double.
Duration: 9 months (preceded by 3 months on either depot). |
| Participants |
Diagnosis: schizophrenia (DSM III).
History: BPRS total score 5‐26, duration ill ‐ mean >2yrs.
N=64.
Age: range 25‐60 yrs.
Sex: 28 M, 33 F.
Setting: community, multicentre. |
| Interventions |
1. Haloperidol decanoate: dose mean 92mg/IM, range 38‐200mg/injection, monthly. N=33.
2. Zuclopenthixol decanoate: dose mean 284mg/IM, range 100‐600mg/injection, monthly. N=23. |
| Outcomes |
Death.
Global Impression (CGI).
Mental state (BPRS, MADRS).
Side effects (Simpson & Angus, UKU). |
| Notes |
Initial 3 month dose adjustment period + supplementary medication, then 6 months where dose constant. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
